Oryzon Genomics SA Cash Flow Conversion Efficiency
Oryzon Genomics SA cash flow conversion efficiency. Based on the latest financial reports, Oryzon Genomics SA (ORY) has a cash flow conversion efficiency ratio of -0.031x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.82 Million USD) by net assets (€78.54 Million ≈ $91.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oryzon Genomics SA (2013–2025)
Cash flow conversion efficiency of Oryzon Genomics SA from 2013 to 2025. This chart illustrates how Oryzon Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oryzon Genomics SA (ORY) share price today for real-time trading data and today's change.
Oryzon Genomics SA Cash Flow Conversion Ratio Explained
Oryzon Genomics SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oryzon Genomics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oryzon Genomics SA ranked by their cash flow conversion efficiency. Also see Oryzon Genomics SA market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etteplan Oyj
HE:ETTE
|
0.031x |
|
Armac Locacao Logistica
SA:ARML3
|
-0.058x |
|
Air Asia Co Ltd
TW:2630
|
-0.006x |
|
D2L Inc
TO:DTOL
|
0.402x |
|
BAIRONG INC.CL.B -00002
F:6B5
|
N/A |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
0.121x |
|
Archimedes Tech SPAC Partners II Co. Unit
NASDAQ:ATIIU
|
0.000x |
|
ES Cube Co. Ltd
KQ:050120
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Oryzon Genomics SA (2013–2025)
The table below shows the annual cash flow conversion efficiency of Oryzon Genomics SA from 2013 to 2025. Review Oryzon Genomics SA free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €117.85 Million ≈ $137.78 Million |
€-2.36 Million ≈ $-2.75 Million |
-0.020x | +69.41% |
| 2024-12-31 | €87.04 Million ≈ $101.76 Million |
€-5.69 Million ≈ $-6.65 Million |
-0.065x | -829.69% |
| 2023-12-31 | €81.77 Million ≈ $95.60 Million |
€-574.96K ≈ $-672.19K |
-0.007x | +72.38% |
| 2022-12-31 | €72.57 Million ≈ $84.84 Million |
€-1.85 Million ≈ $-2.16 Million |
-0.025x | +49.97% |
| 2021-12-31 | €71.26 Million ≈ $83.31 Million |
€-3.63 Million ≈ $-4.24 Million |
-0.051x | +19.79% |
| 2020-12-31 | €75.93 Million ≈ $88.77 Million |
€-4.82 Million ≈ $-5.63 Million |
-0.063x | -29.04% |
| 2019-12-31 | €80.02 Million ≈ $93.55 Million |
€-3.93 Million ≈ $-4.60 Million |
-0.049x | -233.08% |
| 2018-12-31 | €45.13 Million ≈ $52.76 Million |
€-666.09K ≈ $-778.73K |
-0.015x | +89.20% |
| 2017-12-31 | €34.43 Million ≈ $40.25 Million |
€-4.71 Million ≈ $-5.50 Million |
-0.137x | +37.94% |
| 2016-12-31 | €22.73 Million ≈ $26.57 Million |
€-5.01 Million ≈ $-5.85 Million |
-0.220x | -1262.00% |
| 2015-12-31 | €27.59 Million ≈ $32.26 Million |
€523.14K ≈ $611.61K |
0.019x | -97.83% |
| 2014-12-31 | €13.89 Million ≈ $16.24 Million |
€12.13 Million ≈ $14.18 Million |
0.873x | +6.01% |
| 2013-12-31 | €14.73 Million ≈ $17.22 Million |
€12.13 Million ≈ $14.18 Million |
0.823x | -- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more